1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 25, 2025 05:27 ET (10:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.